JONATHAN E DOWELL
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology DALLAS, TX NPI 1497724983
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX Takeda Pharmaceuticals U.S.A., Inc. All categories
General Payments — all program years on this page
$30,409.54
- Category: General Payments
- Program years: PY2018–2023
- Record count: 28
- As of (CMS publication): 2026-01-23
Latest program year (PY2023): $6,270.77 across 6 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2023) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,563.00 | 3 |
| Honoraria | $1,500.00 | 1 |
| Food and Beverage | $207.77 | 2 |
By paying entity
Latest program year (PY2023) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $2,295.00 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $1,673.08 | 2 |
| Regeneron Healthcare Solutions, Inc. | $1,568.00 | 1 |
| JAZZ PHARMACEUTICALS INC. | $700.00 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $34.69 | 1 |
By program year
Records — PY2023 (6)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1048226901 | Catalyst Pharmaceuticals, Inc. | $1,500.00 | 06/15/2023 | Honoraria | Undisputed | 01/23/2026 | View at CMS |
| 1048226903 | Catalyst Pharmaceuticals, Inc. | $173.08 | 06/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1055380581 | Takeda Pharmaceuticals U.S.A., Inc. | $2,295.00 | 05/10/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1058431631 | JAZZ PHARMACEUTICALS INC. | $700.00 | 10/27/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1059047917 | Puma Biotechnology, Inc. | $34.69 | 04/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 999157463 | Regeneron Healthcare Solutions, Inc. | $1,568.00 | 10/20/2023 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.